Severe acute respiratory syndrome coronavirus 2 transaminase elevation likely of non-hepatic origin, with protection from older age and vaccination

严重急性呼吸综合征冠状病毒2转氨酶升高可能并非肝脏来源,老年人和接种疫苗者可获得保护。

阅读:1

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has known liver tropism. Multiple reports and studies demonstrated liver injury early in the pandemic. This retrospective cross-sectional comparison evaluates predictors of transaminase elevation during acute SARS-CoV2 infection, with particular interest in evaluating whether vaccination is associated with transaminase elevations. We extracted electronic medical record data for pediatric SARS-CoV2 patients presenting at safety net hospitals in Brooklyn, NY, between March 2020 and March 2022 with a coincident comprehensive metabolic panel, without multisystem inflammatory syndrome in children, prior liver disease and sickle cell disease (n = 133): 79.2% Black and 87% non-Hispanic. Transaminase elevation was more common among younger patients and patients requiring hospitalization or intensive care unit care. Vaccination was associated with lower quantitative levels of transaminase elevation but not the binary indicator for elevated transaminases. In aggregate, our results suggest transaminase elevation is a function of SARS-CoV2 disease severity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。